Spots can also look very different depending on your skin tone. Some pink, red, or brown spots are more obvious on fair to ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.

Number 3: Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the former’s ...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties ...